表紙
市場調查報告書

多囊性腎臟病治療藥的全球市場:2019年∼2023年

Global Polycystic Kidney Disease Drugs Market 2019-2023

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 881643
出版日期 內容資訊 英文 125 Pages
訂單完成後即時交付
價格
多囊性腎臟病治療藥的全球市場:2019年∼2023年 Global Polycystic Kidney Disease Drugs Market 2019-2023
出版日期: 2019年06月17日內容資訊: 英文 125 Pages
簡介

由於對開發有效治療及診斷罕見疾病的藥物的關注高漲,這鼓勵了美國FDA和EMA等組織為基礎公司提供特殊的法規指定。這為公司提供了諸如臨床試驗和協議援助的稅收抵免等福利。據此可幫助供應商輕鬆推出藥物,這將有助創造收入。因此,在預測期內,特殊監管指定將推動多囊性腎臟病藥物市場的成長,年複合成長率將超過6%。

本報告提供全球多囊性腎臟病治療藥市場相關調查分析,市場規模及成長率,市場趨勢,市場的推動要素與課題,市場機會驗證,再加上主要供應商等相關的系統性資訊。

目錄

第1章 摘要整理

第2章 調查範圍

  • 簡介1
  • 簡介2
  • 美金的貨幣換算比率

第3章 市場情形

  • 市場生態系統
  • 市場特徵
  • 市場區隔分析

第4章 市場規模

  • 市場定義
  • 市場規模(2018年)
  • 市場規模及預測(2018年∼2023年)

第5章 波特的五力分析

  • 買主談判力
  • 供應商談判力
  • 新加入廠商的威脅
  • 替代品的威脅
  • 競爭對手的威脅
  • 市場情況

第6章 開發平台分析

第7章 市場區隔:各類型

  • 市場區隔:各類型
  • 各類型比較:市場規模及預測(2018年∼2023年)
  • ADPKD(平常染色體優性遺傳型)
  • ARPKD(平常染色體隱性遺傳型)
  • 市場機會:各類型

第8章 客戶形勢

第9章 各地區形勢

  • 各地區市場區隔
  • 各地區比較:市場規模及預測(2018年∼2023年)
  • 北美
  • 歐洲
  • 亞洲
  • 其他地區
  • 主要國家
  • 市場機會

第10章 決策架構

第11章 成長要素與課題

  • 市場成長要素
  • 市場課題

第12章 市場趨勢

  • 研究資金的增加
  • 有利的償付政策
  • 腎臟病的認識高漲

第13章 業者情勢

  • 概要
  • 創造性破壞狀況
  • 競爭模式

第14章 供應商分析

  • 交易廠商
  • 供應商分類
  • 供應商的市場定位
  • Johnson & Johnson Services Inc.
  • Merck & Co., Inc.
  • 大塚集團
  • Reata Pharmaceuticals Inc.
  • Sanofi

第15章 附錄

  • 調查方法
  • 簡稱的清單
  • 供應商的市場定位定義

第16章 關於TECHNAVIO

目錄
Product Code: IRTNTR31525

About this market

Polycystic kidney disease is a genetic disorder in which clusters of cysts develop primarily within the kidneys, causing kidneys to enlarge and lose function over time. Technavio's polycystic kidney disease drugs market analysis considers the revenue generation from both autosomal dominant polycystic kidney disease (ADPKD), and autosomal recessive polycystic kidney disease (ARPKD). Our analysis also considers the sales of polycystic kidney disease drugs in North America, Europe, Asia, and ROW. In 2018, the ARPKD segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as the growing prevalence of the disease will play a significant role in the ARPKD segment to maintain its market position. Our global polycystic kidney disease drugs market report looks at factors such as the high prevalence of chronic kidney diseases, special regulatory designations, and the increasing R&D for developing new drugs. However, the lack of approved drugs, availability of substitute treatment options, and stringent regulations may hamper the growth of the polycystic kidney disease drugs industry over the forecast period.

Overview

Special regulatory designations

The growing focus on developing and evaluating drugs that effectively cure and diagnose rare diseases is encouraging organizations such as the US FDA and EMA to provide special regulatory designations to underlying companies. This provides companies with benefits such as tax credits for clinical trials and protocol assistance. These designations help vendors to easily launch drugs, which will help them in generating revenues. Thus, the special regulatory designations will fuel the growth of the polycystic kidney disease drugs market at a CAGR of more than 6% during the forecast period.

Favorable reimbursement policies

The high cost of off-label drugs and the approved novel drug for the treatment of polycystic kidney disease makes it challenging for patients to afford it. Hence, government and non-government organizations are introducing reimbursement policies to help patients in availing the treatment. These policies are further encouraging vendors to increase investments in R&D. Thus, the presence of favorable reimbursement policies will fuel the growth of the market.

For the detailed list of factors that will drive the global polycystic kidney disease drugs market during the forecast period 2019-2023, view our report.

Competitive Landscape

With the presence of several major players, the global polycystic kidney disease drugs market is moderately fragmented. Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading polycystic kidney disease drugs providers, that include Johnson & Johnson Services Inc., Merck & Co., Inc., Otsuka Holdings Co. Ltd., Reata Pharmaceuticals Inc., and Sanofi.

Also, the polycystic kidney disease drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: PIPELINE ANALYSIS

PART 07: MARKET SEGMENTATION BY TYPE

  • Market segmentation by type
  • Comparison by type
  • ADPKD - Market size and forecast 2018-2023
  • ARPKD - Market size and forecast 2018-2023
  • Market opportunity by type

PART 08: CUSTOMER LANDSCAPE

PART 09: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 10: DECISION FRAMEWORK

PART 11: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 12: MARKET TRENDS

  • Increasing research funding
  • Favorable reimbursement policies
  • Growing awareness about kidney diseases

PART 13: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

PART 14: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Johnson & Johnson Services Inc.
  • Merck & Co., Inc.
  • Otsuka Holdings Co. Ltd.
  • Reata Pharmaceuticals Inc.
  • Sanofi

PART 15: APPENDIX

  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors

PART 16: EXPLORE TECHNAVIO

List of Exhibits

  • Exhibit 01: Global pharmaceuticals market
  • Exhibit 02: Segments of global pharmaceuticals market
  • Exhibit 03: Market characteristics
  • Exhibit 04: Market segments
  • Exhibit 05: Market definition - Inclusions and exclusions checklist
  • Exhibit 06: Market size 2018
  • Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 09: Five forces analysis 2018
  • Exhibit 10: Five forces analysis 2023
  • Exhibit 11: Bargaining power of buyers
  • Exhibit 12: Bargaining power of suppliers
  • Exhibit 13: Threat of new entrants
  • Exhibit 14: Threat of substitutes
  • Exhibit 15: Threat of rivalry
  • Exhibit 16: Market condition - Five forces 2018
  • Exhibit 17: Some of the clinical stage drugs for polycystic kidney disease
  • Exhibit 18: Type - Market share 2018-2023 (%)
  • Exhibit 19: Comparison by type
  • Exhibit 20: ADPKD - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 21: ADPKD - Year-over-year growth 2019-2023 (%)
  • Exhibit 22: ARPKD - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 23: ARPKD - Year-over-year growth 2019-2023 (%)
  • Exhibit 24: Market opportunity by type
  • Exhibit 25: Customer landscape
  • Exhibit 26: Market share by geography 2018-2023 (%)
  • Exhibit 27: Geographic comparison
  • Exhibit 28: North America - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 29: North America - Year-over-year growth 2019-2023 (%)
  • Exhibit 30: Top 3 countries in North America
  • Exhibit 31: Europe - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 32: Europe - Year-over-year growth 2019-2023 (%)
  • Exhibit 33: Top 3 countries in Europe
  • Exhibit 34: Asia - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 35: Asia - Year-over-year growth 2019-2023 (%)
  • Exhibit 36: Top 3 countries in Asia
  • Exhibit 37: ROW - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 38: ROW - Year-over-year growth 2019-2023 (%)
  • Exhibit 39: Top 3 countries in ROW
  • Exhibit 40: Key leading countries
  • Exhibit 41: Market opportunity
  • Exhibit 42: Prevalence of chronic kidney diseases per 100 people
  • Exhibit 43: Impact of drivers and challenges
  • Exhibit 44: Vendor landscape
  • Exhibit 45: Landscape disruption
  • Exhibit 46: Vendors covered
  • Exhibit 47: Vendor classification
  • Exhibit 48: Market positioning of vendors
  • Exhibit 49: Johnson & Johnson Services Inc. - Vendor overview
  • Exhibit 50: Johnson & Johnson Services Inc. - Business segments
  • Exhibit 51: Johnson & Johnson Services Inc. - Organizational developments
  • Exhibit 52: Johnson & Johnson Services Inc. - Geographic focus
  • Exhibit 53: Johnson & Johnson Services Inc. - Segment focus
  • Exhibit 54: Johnson & Johnson Services Inc. - Key offerings
  • Exhibit 55: Johnson & Johnson Services Inc. - Key customers
  • Exhibit 56: Merck & Co. Inc. - Vendor overview
  • Exhibit 57: Merck & Co. Inc. - Business segments
  • Exhibit 58: Merck & Co. Inc. - Organizational developments
  • Exhibit 59: Merck & Co. Inc. - Geographic focus
  • Exhibit 60: Merck & Co. Inc. - Segment focus
  • Exhibit 61: Merck & Co. Inc. - Key offerings
  • Exhibit 62: Merck & Co. Inc. - Key customers
  • Exhibit 63: Otsuka Holdings Co. Ltd. - Vendor overview
  • Exhibit 64: Otsuka Holdings Co. Ltd. - Business segments
  • Exhibit 65: Otsuka Holdings Co. Ltd. - Organizational developments
  • Exhibit 66: Otsuka Holdings Co. Ltd. - Geographic focus
  • Exhibit 67: Otsuka Holdings Co. Ltd. - Segment focus
  • Exhibit 68: Otsuka Holdings Co. Ltd. - Key offerings
  • Exhibit 69: Otsuka Holdings Co. Ltd. - Key customers
  • Exhibit 70: Reata Pharmaceuticals Inc. - Vendor overview
  • Exhibit 71: Reata Pharmaceuticals Inc. - Organizational developments
  • Exhibit 72: Reata Pharmaceuticals Inc. - Key offerings
  • Exhibit 73: Reata Pharmaceuticals Inc. - Key customers
  • Exhibit 74: Sanofi - Vendor overview
  • Exhibit 75: Sanofi - Business segments
  • Exhibit 76: Sanofi - Organizational developments
  • Exhibit 77: Sanofi - Geographic focus
  • Exhibit 78: Sanofi - Segment focus
  • Exhibit 79: Sanofi - Key offerings
  • Exhibit 80: Sanofi - Key customers
  • Exhibit 81: Validation techniques employed for market sizing
  • Exhibit 82: Definition of market positioning of vendors